|Application ||WB, E|
|Other Accession||O09015, P50540, NP_005953.4, NP_569157.2, NP_001008541.1|
|Calculated MW||26062 Da|
|Antigen Region||53-82 aa|
|Other Names||Max-interacting protein 1, Max interactor 1, Class C basic helix-loop-helix protein 11, bHLHc11, MXI1, BHLHC11|
|Target/Specificity||This MXI1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 53-82 amino acids from the Central region of human MXI1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||MXI1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional repressor. MXI1 binds with MAX to form a sequence-specific DNA-binding protein complex which recognizes the core sequence 5'-CAC[GA]TG-3'. MXI1 thus antagonizes MYC transcriptional activity by competing for MAX.|
|Tissue Location||High levels found in the brain, heart and lung while lower levels are seen in the liver, kidney and skeletal muscle|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Expression of the c-myc gene, which produces an oncogenic transcription factor, is tightly regulated in normal cells but is frequently deregulated in human cancers. The protein encoded by this gene is a transcriptional repressor thought to negatively regulate MYC function, and is therefore a potential tumor suppressor. This protein inhibits the transcriptional activity of MYC by competing for MAX, another basic helix-loop-helix protein that binds to MYC and is required for its function. Defects in this gene are frequently found in patients with prostate tumors. Three alternatively spliced transcripts encoding different isoforms have been described. Additional alternatively spliced transcripts may exist but the products of these transcripts have not been verified experimentally.
Lofstedt, T., et al. Exp. Cell Res. 315(11):1924-1936(2009)
Baranzini, S.E., et al. Hum. Mol. Genet. 18(4):767-778(2009)
Tsao, C.C., et al. Cancer Biol. Ther. 7(10):1619-1627(2008)
Suo, X.H., et al. Zhonghua Xue Ye Xue Za Zhi 28(11):745-749(2007)
Dugast-Darzacq, C., et al. FEBS J. 274(17):4643-4653(2007)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.